demonstrated an increasing trend of CTLA-4 expression in CRC tissues and cell lines, and treatment with capecitabine effectively suppressed the expression of CTLA-4 in CRC cells, suggesting a potential bridge between immunotherapy approaches and chemotherapy (40). The gene discussed is CTLA4; the disease is colorectal carcinoma.